These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 34674115)
1. Difelikefalin: First Approval. Deeks ED Drugs; 2021 Nov; 81(16):1937-1944. PubMed ID: 34674115 [TBL] [Abstract][Full Text] [Related]
2. Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus. Spencer RH; Noonan PK; Marbury T; Menzaghi F BMC Nephrol; 2024 Oct; 25(1):351. PubMed ID: 39402448 [TBL] [Abstract][Full Text] [Related]
3. Difelikefalin: A New κ-Opioid Receptor Agonist for the Treatment of Hemodialysis-Dependent Chronic Kidney Disease-Associated Pruritus. Fugal J; Serpa SM Ann Pharmacother; 2023 Apr; 57(4):480-488. PubMed ID: 35942600 [TBL] [Abstract][Full Text] [Related]
4. Intravenous difelikefalin for the treatment of hemodialysis pruritus. Mahmoud RH; Mahmoud O; Yosipovitch G Expert Rev Clin Immunol; 2024; 20(1):31-37. PubMed ID: 37847514 [TBL] [Abstract][Full Text] [Related]
5. Difelikefalin for pruritus associated with renal disease. Manenti L; Fenaroli P Drugs Today (Barc); 2022 Sep; 58(9):427-435. PubMed ID: 36102903 [TBL] [Abstract][Full Text] [Related]
6. Impact of Difelikefalin on the Health-Related Quality of Life of Haemodialysis Patients with Moderate-To-Severe Chronic Kidney Disease-Associated Pruritus: A Single-Arm Intervention Trial. Fotheringham J; Guest J; Latus J; Lerma E; Morin I; Schaufler T; Soro M; Ständer S; Zeig S Patient; 2024 Mar; 17(2):203-213. PubMed ID: 38196014 [TBL] [Abstract][Full Text] [Related]
7. Difelikefalin (Korsuva) for chronic kidney disease-associated pruritus. Med Lett Drugs Ther; 2022 Feb; 64(1643):18-19. PubMed ID: 35134047 [No Abstract] [Full Text] [Related]
8. Phase 2 Trial of Difelikefalin in Notalgia Paresthetica. Kim BS; Bissonnette R; Nograles K; Munera C; Shah N; Jebara A; Cirulli J; Goncalves J; Lebwohl M; N Engl J Med; 2023 Feb; 388(6):511-517. PubMed ID: 36780675 [TBL] [Abstract][Full Text] [Related]
10. Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis. Rastogi A; Fishbane S; Lerma E Expert Rev Clin Pharmacol; 2023 May; 16(5):387-400. PubMed ID: 37010031 [TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis. Thokala P; Hnynn Si PE; Hernandez Alava M; Sasso A; Schaufler T; Soro M; Fotheringham J Pharmacoeconomics; 2023 Apr; 41(4):457-466. PubMed ID: 36735201 [TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus. Yosipovitch G; Awad A; Spencer RH; Munera C; Menzaghi F J Am Acad Dermatol; 2023 Aug; 89(2):261-268. PubMed ID: 37059302 [TBL] [Abstract][Full Text] [Related]
13. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F; N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883 [TBL] [Abstract][Full Text] [Related]
14. An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease. Lipman ZM; Yosipovitch G Expert Opin Pharmacother; 2021 Apr; 22(5):549-555. PubMed ID: 33190563 [No Abstract] [Full Text] [Related]
15. Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2. Fishbane S; Clegg DJ; Lerma EV; Rastogi A; Budden J; Morin I; Wen W; Menzaghi F; Topf J Am J Nephrol; 2024; 55(3):329-333. PubMed ID: 38253036 [TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of difelikefalin for pruritus in hemodialysis patients: a systematic review and meta-analysis of randomized controlled trials. Saeed A; Elshnoudy IA; Khlidj Y; Radwan R; Kamal M; Hamdi M; Alsaid A; Turkmani M; Abuelazm M Ren Fail; 2024 Dec; 46(2):2384590. PubMed ID: 39091079 [TBL] [Abstract][Full Text] [Related]
17. Difelikefalin for Hemodialysis Patients with Pruritus in Japan. Narita I; Tsubakihara Y; Takahashi N; Ebata T; Uchiyama T; Marumo M; Okamura S; Gejyo F; NEJM Evid; 2023 Nov; 2(11):EVIDoa2300094. PubMed ID: 38320524 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial. Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F; JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180 [TBL] [Abstract][Full Text] [Related]
19. [Clinical Research Progress on Using κ-Opioid Receptor Agonists to Treat Uremic Pruritus]. Yang M; Li Y; Yang Q; Su B Sichuan Da Xue Xue Bao Yi Xue Ban; 2024 Jul; 55(4):1044-1048. PubMed ID: 39170011 [TBL] [Abstract][Full Text] [Related]
20. Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study. Weiner DE; Vervloet MG; Walpen S; Schaufler T; Munera C; Menzaghi F; Wen W; Bhaduri S; Germain MJ; Kidney Med; 2022 Oct; 4(10):100542. PubMed ID: 36185706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]